Regent’s Park announces an unprecedented 100% service uptime record at Addenbrooke’s Hospital, Cambridge

[frame src=”https://www.rphc.co.uk/wp-content/uploads/2008/06/vpn-reliable.jpg” width=”300″ height=”199″ lightbox=”on” title=”Regent’s Park announces an unprecedented 100% service uptime record at Addenbrooke’s Hospital, Cambridge” align=”left” ]
Regent’s Park Heart Clinics Ltd. (Regent’s Park), an independent healthcare company specialising in the diagnosis and treatment of heart disease, today announced an unprecedented 100% service uptime over the duration of its contract to provide mobile cath lab services at Addenbrooke’s Hospital in Cambridge. Addenbrooke’s Hospital is part of Cambridge University Hospitals NHS Foundation Trust. Addenbrooke’s is the teaching hospital for the University of Cambridge with a reputation for clinical excellence both nationally and internationally.

Dr. Michael O’Sullivan, Director of Cardiology & Consultant Cardiologist at Addenbrooke’s Hospital said “Regent’s Park have provided an excellent service to our Trust over the last two years. There has been a 100% service uptime record with not a single cancellation of a catheter lab session. Our patients have benefited enormously with a large reduction in inpatient waiting times for cardiac catheterisation procedures.”

Dr. O’Sullivan added: “Everyone in our Trust has been extremely impressed and we would have no hesitation in recommending their services to other NHS hospitals. The service has allowed our Trust with the perfect way to expand its invasive cardiology services and Regent’s Park have also helped us to develop our fixed site catheter lab services that will be opening shortly. We expect them to be our long term cardiology partners and I am sure more news on this exciting partnership will follow shortly from both parties.”

Dr. Ohri, Chief Executive of Regent’s Park, said, “It has been a tremendous privilege to work alongside the committed and highly skilled cardiologists and staff at Addenbrooke’s Hospital. We always set ourselves high quality hurdles at Regent’s Park and we are very proud of our 100% service record at Addenbrooke’s. I believe this has been achieved for three main reasons – our strategy of providing brand new cath labs, good operations management and most importantly, the professionalism and teamwork of NHS and Regent’s Park staff.”

Dr. Ohri added: “I would like to use this opportunity to pay a special tribute to the following Regent’s Park staff who through their dedication have made this partnership so successful over the last two years:

[list type=”bullet2″]

  • Radiographers: Andrew White, Elizabeth Wishart, Ian Court & Bruce Atkins;
  • Cardiac Physiologists: Kenny Treacher & Michael Octave; and
  • Cardiac Nurses: Bryn Webber, Natalie Quinnell, Mo Mesad & Sue Ansell.”

[/list]

Regent’s Park is an independent company dedicated to creating world-class centres for the diagnosis and treatment of heart disease. The company develops, owns and operates diagnostic and treatment facilities focusing exclusively on cardiovascular disease in partnership with leading hospitals and groups of cardiologists across the United Kingdom. Regent’s Park has been a national provider of cardiol ogy services to the NHS since 2003, and has provided invasive cardiology procedures to over 10,000 patients through its facilities – coronary angiograms, coronary angioplasty, cardiac electrophysiology, defibrillator and pacing procedures. Regent’s Park prides itself on its ability to deliver high quality, cost effective cardiac care, through excellent service, efficient operations management, well trained staff, and uncompromising professionalism.

The Regent’s Park guiding philosophy is that every patient with heart disease should have access to healthcare of a world-class standard.

Regent’s Park opens second Cardiac Electrophysiology Laboratory at The John Radcliffe Hospital, Oxford

[frame src=”https://www.rphc.co.uk/wp-content/uploads/2007/11/mainthum_1131.jpg” width=”300″ height=”200″ lightbox=”on” title=”Regent’s Park opens second Cardiac Electrophysiology Laboratory at The John Radcliffe Hospital, Oxford” align=”left” ]
Regent’s Park Heart Clinics Ltd. (Regent’s Park), an independent healthcare company specialising in the diagnosis and treatment of heart disease, today announced it opened a second state-of-the-art cardiac electrophysiology (“EP”) and ablation laboratory at The John Radcliffe Hospital in Oxford. The John Radcliffe is a major tertiary cardiothoracic teaching centre providing open-heart surgery and leading-edge cardiology with strong academic links with the medical sciences faculty of Oxford University.

The EP lab was officially opened by Trevor Campbell-Davis, Chief Executive of the Oxford Radcliffe Hospitals NHS Trust and Dr. Stephen Green, Consultant to the Department of Health vascular programme.

Trevor Campbell Davies, Chief Executive, Oxford Radcliffe Hospitals NHS Trust said: “We are pleased to be working with Regent’s Park and thank them for providing us with the ability to expand our capacity during the transition period between the expansion and upgrade of services that is currently underway on the John Radcliffe site.”

Dr. Ohri added: “The delivery of this bespoke lab in just 12 weeks and on budget was achieved through a close working collaborative with the Trust. To our knowledge, we are the only company in the UK or Europe to have developed these type of specialist cardiac arrhythmia laboratories. The inspiration for their development followed an invitation I received to visit the Cleveland Heart Clinic about a year ago. The Cleveland Heart Clinic is considered to be one of the best heart centres in the world, and seeing first hand the size, versatility and technology-driven nature of their cath labs, made me realise the need for us to embrace international best practice and to follow a similar course”.

Bryn Webber, Lead Nurse at Regent’s Park, commented: “Visitors to this lab are surprised by both the amount and the use of the space we have been able to provide within a modular environment. Having worked in and visited many catheter lab facilities across the UK, I really appreciate the importance of the working area and its impact on operational flow and patient saftey. In many ways I feel this modular facility outperforms a number of fixed site catheter labs for its space, layout and clinician friendly feel. For once it feels as though a catheter lab has been built to focus on the needs of catheter lab staff and the patients they serve”.

Dr. Ohri said: “Regent’s Park have taken the strategic decision to invest in the cardiac arrhythmia services marketplace across the UK and have a series of additional specialist EP catheter labs in the pipeline. However, we realise that developing improved working environments for the electrophysiology community is not enough, and that we will also need to focus our efforts on addressing the chronic shortage of appropriately trained EP cardiac physiologists and arrhythmia nurses. We intend to respond to this shortage by putting in place innovative recruitment, training and retention strategies over the coming months and years”.

Regent’s Park is an independent company dedicated to creating world-class centres for the diagnosis and treatment of heart disease. The company develops, owns and operates diagnostic and treatment facilities focusing exclusively on cardiovascular disease in partnership with leading hospitals and groups of cardiologists across the United Kingdom. The company was founded in 2002 to pioneer joint ventures with the NHS across the field of cardiac services, delivering expertise, quality and innovation in one value for money package.

Regent’s Park prides itself on its ability to deliver high quality, cost effective cardiac care, through excellent service, efficient operations management, well trained staff, and uncompromising professionalism.

Its guiding philosophy is that every patient with heart disease should have access to healthcare of a worldclass standard.

Dr. Ohri, Chief Executive, Regent’s Park Heart Clinics responded: “Regent’s Park are very proud to have worked with the Trust since 2004, and were delighted to have been asked to expand EP service provision. This second EP lab is the most modern and advanced in our fleet, and its deployment reflects both the continuing growth within the cardiac arrhythmia services marketplace as well as the excellent relationship we have developed with the Trust.

The cath lab was delivered in three sections, using a super-size 121 metre high crane weighing 500 tonnes, before being lowered into a small quadrant within the John Radcliffe Hospital beside the Cardiac Investigations Annexe.

Regent’s Park announces the award of a contract to provide Invasive Cardiology Services at Addenbrooke’s Hospital, Cambridge

[frame src=”https://www.rphc.co.uk/wp-content/uploads/2006/05/addensbrook.jpg” width=”300″ height=”187″ lightbox=”on” title=”Regent’s Park announces the award of a contract to provide Invasive Cardiology Services at Addenbrooke’s Hospital, Cambridge” align=”left” ]
Regent’s Park Heart Clinics Ltd. (Regent’s Park), an independent healthcare company specialising in the diagnosis and treatment of heart disease, today announced it has been awarded a long-term contract to provide invasive cardiology services at Addenbrooke’s Hospital in Cambridge. Addenbrooke’s Hospital is part of Cambridge University Hospitals NHS Foundation Trust. Addenbrooke’s is the teaching hospital for the University of Cambridge, a centre for specialist services, and a leader in research and development.

Dr. Ohri, Chief Executive of Regent’s Park said: “Winning this fiercely competitive tender is terrific news for our company. The success helps develop our nationwide distribution network of healthcare services and confirms our position as the UK’s leading managed cardiology services provider. The award also fits extremely well with our strategy to forge links with leading University Teaching Hospitals from across the NHS. Addenbrooke’s has a formidable reputation as a world-class centre of excellence in biomedical sciences and it will be a huge privilege for our staff and organisation to be working alongside this great institution.”

Dr. Ohri added: “We will be providing Cambridge with one of our highly-bespoke cardiac SuperLabsTM. The Cambridge SuperLabTM will be equipped with a brand new Siemens Artis dFC Cardiology System – This is state-of-the-art flat plate detector technology designed to improve the visualisation of detailed coronary anatomy. It will allow heart disease in our patients to be detected and managed more easily.”

Cambridge University Hospitals NHS Foundation Trust has an income of over £360 million and around 1100 beds, it employs over 6500 staff dedicated to the provision of a wide range of clinical and non-clinical services. The Trust is a leading international centre for biomedical research and medical education, and shares its site with the University of Cambridge, the Medical Research Council, the Wellcome Trust, the British Heart Foundation and Glaxo SmithKline. Addenbrooke’s is a national and regional centre for cancer services, liver transplants, organ transplantation, neurosciences and genetics.

Regent’s Park is an independent company dedicated to creating world-class centres for the diagnosis and treatment of heart disease. The company develops, owns and operates diagnostic and treatment facilities focusing exclusively on cardiovascular disease in partnership with leading hospitals and groups of cardiologists across the United Kingdom. Regent’s Park has been a national provider of cardiology services to the NHS since 2003, and has provided invasive cardiology procedures to over 8,500 patients through its facilities – coronary angiograms, coronary angioplasty, cardiac electrophysiology, defibrillator and pacing procedures. Regent’s Park prides itself on its ability to deliver high quality, cost effective cardiac care, through excellent service, efficient operations management, well trained staff, and uncompromising professionalism.

The Regent’s Park guiding philosophy is that every patient with heart disease should have access to healthcare of a world-class standard.

Regent’s Park provides Europe’s First Modular Cardiac Electrophysiology Service at The John Radcliffe Hospital, Oxford

[frame src=”https://www.rphc.co.uk/wp-content/uploads/2004/11/org_5681.jpg” width=”300″ height=”300″ lightbox=”on” title=”Regent’s Park provides Europe’s First Modular Cardiac Electrophysiology Service at The John Radcliffe Hospital, Oxford” align=”left” ]
Regent’s Park Heart Clinics Ltd. (Regent’s Park), an independent healthcare company specialising in the diagnosis and treatment of heart disease, today announced it is providing modular cardiac electrophysiology (“EP”) and ablation services at The John Radcliffe Hospital in Oxford. The John Radcliffe is a major tertiary cardiothoracic teaching centre providing open-heart surgery and advanced cardiology with strong academic links with the medical sciences faculty of Oxford University.

Dr. Ohri, Chief Executive of Regent’s Park said: “We are extremely proud to have won this contract to build upon the existing cardiac rhythm management services available in Oxford using one of our specially equipped laboratories. We call them “SuperLabsTM “because of their huge size, state-of-the-art technology and their versatility. The Oxford SuperLabTM was designed, built, equipped and installed in just15 weeks at a cost of around £2 million. It is the largest and most advanced of its kind anywhere in the world, and was designed and equipped by our engineers to meet the specific requirements of EP cardiologists in Oxford.” Dr. Ohri added: “The laboratory has been fitted with two state of the art EP & ablation systems, piped anaesthetic gases for providing general anaesthesia for more complex cases and is digitally networked into the main hospital system. It even has its own kitchen and image archiving room to reduce the need for staff to move to and from the main hospital.”

Dr. Tim Betts, Consultant Electrophysiologist, at the John Radcliffe commented: “It’s excellent – the laboratory feels and acts like the real thing and it has all the up to date equipment. It is purpose built with all the essential services tidied away in the floor and ceiling.”

Ruth Titchener, Head Cardiac Nurse, at the John Radcliffe said: “Since this service commenced, we have been able to introduce transfers from local hospitals on a day case basis where before they had to wait for a bed in cardiology. Patients would wait for a month, now it is five days”.

“By shifting all of the EP workload into the SuperLabTM from the main catheter labs in the hospital, operational workflows become more streamlined, providing the main catheter labs with more capacity to perform diagnostic and interventional cardiology. We believe this type of operations model, by removing competing pressures for catheter laboratory space, is a win-win situation for everyone,” commented Andrew White, Superintendent Radiographer, at Regent’s Park.

EP and ablation services are one of the fastest growing sub-specialties within interventional cardiology, with an estimated 700,000 people in the UK suffering from some form of cardiac rhythm problem the demand to perform more interventions has never been greater. There are only around 65 cardiologists based in about 40 hospitals in the UK1 trained to do these type of procedures compared to around 2,400 cardiologists in over 650 hospitals in the USA2 – approximately 8 times as many cardiologists per capita of the population. Staffing as well as other resources constraints are set to be recognised by the Department of Health in a new Arrhythmias chapter in the National Service Framework for Coronary Heart Disease due to be published in March 2005.

Dr. Ohri of Regent’s Park added: “We have long recognised that UK rhythm management services need to be rapidly expanded if we are to provide patients with accessible and high quality standards of care. We believe this type of dedicated laboratory service model, which has been re-designed to meet the needs of both doctors and patients, will help to concentrate expertise and so achieve economies of scale, high volumes and good results.”

“Arrhythmias encompass a broad spectrum, from benign tachycardias that are not life threatening but do cause disabling symptoms, to dangerous, life-threatening tachycardias that are a leading cause of sudden cardiac death in the developed world. Over the last decade, huge advances in knowledge and technology now enable electrophysiologists to prevent or cure the vast majority of arrhythmias, as well as providing sophisticated device therapies for heart failure patients. This has resulted in an exponential growth of patients who could now benefit from treatment. To meet this need, we require the equipment and resources that a modern, state-of-the art facility such as the SuperLab can provide,” said Dr. Tim Betts.

Regent’s Park is an independent company dedicated to creating world-class centres for the diagnosis and treatment of heart disease. The company develops, owns and operates diagnostic and treatment facilities focusing exclusively on cardiovascular disease in partnership with leading hospitals and groups of cardiologists across the United Kingdom. Regent’s Park has been a national provider of cardiology services to the NHS since 2003, and has provided invasive cardiology procedures to over 4,000 patients through its facilities – coronary angiograms, coronary angioplasty, cardiac electrophysiology, defibrillator and pacing procedures. Regent’s Park prides itself on its ability to deliver high quality, cost effective cardiac care, through excellent service, efficient operations management, well trained staff, and uncompromising professionalism.

The Regent’s Park guiding philosophy is that every patient with heart disease should have access to healthcare of a world-class standard.

Regent’s Park announces the successful completion of Cardiac Catheterisation Services at Worthing Hospital

[frame src=”https://www.rphc.co.uk/wp-content/uploads/2004/08/asd889j.jpg” width=”300″ height=”200″ lightbox=”on” title=”Regent’s Park announces the successful completion of Cardiac Catheterisation Services at Worthing Hospital” align=”left” ]
Regent’s Park Heart Clinics Ltd. (Regent’s Park), an independent healthcare company specialising in the diagnosis and treatment of heart disease, today announced it has successfully completed a contract to provide cardiac catheterisation services at Worthing Hospital, a 500-bed NHS hospital located on the south coast of England.

Dr. Signy, Consultant Cardiologist at Worthing Hospital said “Regent’s Park have provided a terrific service to our Trust over the last 15 months and we will miss them. Our experience of Regent’s Park was exactly what a public private partnership should be all about. Their personable approach, talented staff and professionally managed service was truly refreshing. The catheter lab they provided came from the United States and it was much larger than previous mobiles we had seen. And whilst size isn’t everything, the extra space provided more storage, better patient workflows and a more pleasant working environment, and we therefore achieved a similar working pattern and workload to that envisaged in our new fixed lab.” Stephen Clarke, Business Manager for Medicine, at Worthing Hospital said: “Regent’s Park provided a reliable and extremely cost-effective solution which I believe was due in part to their low overhead structure as well as their understanding of both the clinical and business aspects of providing a managed cardiology service. Their interim managed service was designed to allow the Trust to ramp-up its internal capabilities in preparation for our own two million pound fixed cardiac laboratory, which opened successfully on 2nd July 2004.”

Rebecca Joyce, Catheter Lab Sister at Worthing Hospital commented: “Regent’s Park were a great company to work with. There was a huge willingness of their staff to work alongside my own. The staff they provide were all very experienced and from major cardiac centers such as Southampton and Brighton. They provided free training for our staff, covered annual and study leave and there were never any staff shortages.”

Dr. Ohri, Chief Executive of Regent’s Park, said, “It has been a privilege to work alongside the committed and highly skilled cardiologists and staff at Worthing Hospital. There had been a tremendous spirit of partnership which as an organisation we strive to replicate across all our service operations. Our Company provided a combination of managed services at Worthing over a period of 15 months. A visiting mobile service for the first 10 months, changing to a modular (fixed-site) service over the last 5 months. I believe the numbers which speak for themselves are a testament to the hard work of all the staff: 879 diagnostic angiograms with 96.4% service uptime and an impressive reduction in day case waiting times from over 12 months to around 5 months”.

Dr. Ohri added, “We strive to work with the NHS, cardiologists and local communities to develop managed cardiology services that reduce patient waiting times in a safe, high quality and cost-effective environment. I am pleased the service has proved so successful and I wish everyone at Worthing an equal amount of success with their new catheterisation service.”

Regent’s Park is an independent company dedicated to creating world-class centres for the diagnosis and treatment of heart disease. The company develops, owns and operates diagnostic and treatment facilities focusing exclusively on cardiovascular disease in partnership with leading hospitals and groups of cardiologists across the United Kingdom. Regent’s Park has been a national provider of cardiology services
to the NHS since 2003, and has provided invasive cardiology procedures to over 2,500 patients through its facilities – coronary angiograms, coronary angioplasty, cardiac electrophysiology, defibrillator and pacing procedures. Regent’s Park prides itself on its ability to deliver high quality, cost effective cardiac care, through excellent service, efficient operations management, well trained staff, and uncompromising professionalism.

The Regent’s Park guiding philosophy is that every patient with heart disease should have access to healthcare of a world-class standard.

Regent’s Park announces the award of a Framework Agreement from the NHS Purchasing and Supply Agency for the Supply of Mobile Cardiac Catheterisation Services

[frame src=”https://www.rphc.co.uk/wp-content/uploads/2003/09/nhs-sign1.jpg” width=”300″ height=”197″ lightbox=”on” title=”Regent’s Park announces the award of a Framework Agreement from the NHS Purchasing and Supply Agency for the Supply of Mobile Cardiac Catheterisation Services” align=”left” ]

Regent’s Park Heart Clinics Ltd. (Regent’s Park), an independent healthcare company specialising in the diagnosis and treatment of heart disease, today announced that it has been awarded a Framework Agreement by the NHS Purchasing and Supply Agency (PASA) for the supply of mobile cardiac catheterisation laboratories and services across NHS trusts and health authorities in England. The Framework Agreement has been awarded for three years, commencing from 1st October 2003, with an option to extend up to 24 months.

Dr. Ohri, Chief Executive of Regent’s Park, said, “This award is great news for Regent’s Park and a welcome endorsement of our dedicated healthcare focus. Despite fierce competition we have confirmed our position as one of the leading players in the healthcare services marketplace for cardiovascular disease. The Framework Agreement enables NHS organisations’ throughout England to purchase our services with the knowledge that we have been thoroughly vetted, both in terms of technical capability and financial security”.

He added, “We share PASA’s dedication to continuous improvement of purchasing and supply, and recognise the essential role that professional procurement needs to have in achieving value for money and service benefits, which impact directly on the quality of patient care and service delivery. By evaluating suppliers to ensure they are of the necessary calibre to supply solutions to the NHS, and negotiating favourable terms for payment, support and implementation, PASA will undoubtedly save NHS Trusts and Authorities both time and money. For us it streamlines the tender and evaluation process and makes it easier to provide these institutions with the specialist services that they need to enhance their cardiovascular product offering, improve efficiency and reduce costs.”

The NHS Purchasing and Supply Agency is an executive agency of the Department of Health and contracts across England for products and services that are strategically critical to the NHS. Wherever possible it uses its aggregated purchasing power to negotiate more favourable contractual and financial terms than would otherwise not necessarily be agreed for individual projects. It works with approximately 350 NHS trusts and health authorities across England, managing national purchasing contracts and influencing an annual NHS spend on goods and services of over £2.6 billion. Its role is to act as a centre of excellence in purchasing and supply matters, and to facilitate best practice and effective purchasing decisions by the NHS. As an integral part of the Department of Health the agency is in a key position to advise on policy and the strategic direction of procurement, and its impact on healthcare, across the NHS.

Regent’s Park is an independent company dedicated to creating world-class centres for the diagnosis and treatment of heart disease. The company develops, owns and operates diagnostic and treatment facilities focusing exclusively on cardiovascular disease in partnership with leading hospitals and groups of cardiologists across the United Kingdom. The company was founded in 2002 to pioneer joint ventures with the NHS across the field of cardiac services, delivering expertise, quality and innovation in one value for money package.

Regent’s Park prides itself on its ability to deliver high quality, cost effective cardiac care, through excellent service, efficient operations management, well trained staff, and uncompromising professionalism.

The Regent’s Park guiding philosophy is that every patient with heart disease should have access to healthcare of a world-class standard.

Regent’s Park Heart Clinics Ltd. are proud to announce an innovative partnership with The Royal Brompton & Harefeld NHS Trust, one of the UK’s foremost cardiac centres

[frame src=”https://www.rphc.co.uk/wp-content/uploads/2003/06/Royal-Brompton-Harefield-007.jpg” width=”300″ height=”180″ lightbox=”on” title=”Regent’s Park Heart Clinics Ltd. are proud to announce an innovative partnership with The Royal Brompton & Harefeld NHS Trust, one of the UK’s foremost cardiac centres” align=”left” ]
Regent’s Park Heart Clinics Ltd. (Regent’s Park), an independent healthcare company specialising in the diagnosis and treatment of heart disease, today announced an innovative partnership with the Royal Brompton and Harefield NHS Trust to jointly develop mobile cardiac catheterisation services.
Dr. Ohri, Chief Executive of Regent’s Park, said, “It is a privilege to be working with the internationally acclaimed Royal Brompton & Harefield NHS Trust. This partnership harnesses valuable resources of both the public and private sector in a way that will improve the delivery of cardiac services and enhance patient care. The partnership allows our company to use our staff and know-how to market and distribute spare cath lab capacity, bringing additional revenue into the trust. It makes perfect sense because all parties win. The Trust benefits financially from the improved utilisation of the laboratory, Regent’s Park benefits from the resources of a leading heart centre and patients benefit from reduced waiting times to diagnose the extent of their heart disease.”
He added, “There is an enormous need for quality healthcare focused on the treatment of heart disease throughout the United Kingdom. We believe in working with the NHS, cardiac specialists and local communities to develop services that will reduce patient waiting times in a safe, high quality and cost-effective environment”.